Result card

  • ETH14: What are the ethical consequences of the assessment of IGG?
English
No adaptation help available for this domain

What are the ethical consequences of the assessment of IGG?

Authors: Plamen Dimitrov, Anelia Koteva

Internal reviewers: Pseudo99 Pseudo99

Currently, administration of intravenous immunoglobulins in patients with Alzheimer’s disease is still at an experimental stage marked by contradictory intermediate results. If clinical trials demonstrate indisputably the effectiveness of immunotherapy, its regular usage will be expected to provide improved quality of life for patients.

 

As already discussed in the previous sections, the reallocation of the limited quantities of immunoglobulins towards the treatment of the increasing number of AD subjects is likely to disturb the therapy of patients with immunodeficiencies or autoimmune diseases, placing IVIG as a treatment option for Alzheimer’s disease in the background. This consideration is with a view to ensuring balanced distribution of healthcare resources for society as a whole, compliant with the principles of justice and interdependence in order to guarantee that they are fairly and rationally exploited by all.

Dimitrov P, Koteva A Result Card ETH14 In: Dimitrov P, Koteva A Ethical analysis In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267